Skip to main content

ERI3 KO cell line available to order. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, Homozygous: 279 bp deletion in exon 1.

Be the first to review this product! Submit a review

Images

Sanger Sequencing - Human ERI3 knockout HeLa cell line (AB265999), expandable thumbnail

Key facts

Cell type
HeLa
Species or organism
Human
Tissue
Cervix
Form
Liquid
Knockout validation
Sanger Sequencing
Mutation description
Knockout achieved by using CRISPR/Cas9, Homozygous: 279 bp deletion in exon 1

Alternative names

Recommended products

ERI3 KO cell line available to order. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, Homozygous: 279 bp deletion in exon 1.

Key facts

Cell type
HeLa
Form
Liquid
Mutation description
Knockout achieved by using CRISPR/Cas9, Homozygous: 279 bp deletion in exon 1
Disease
Adenocarcinoma
Concentration
Loading...

Properties

Gene name
ERI3
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous

Quality control

STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level
EU: 2 US: 2
Adherent/suspension
Adherent
Gender
Female

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium
DMEM (High Glucose) + 10% FBS
Cryopreservation medium
Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Storage

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Notes

Recommended control: Human wild-type HeLa cell line (ab255928). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

The ERI3 protein also known as EC-RNA Interacting Protein 3 functions mechanistically in the processing of RNA. This protein has a molecular mass of approximately 72 kDa. ERI3 expression occurs across several tissues with notable presence in the liver and kidneys. Its role in RNA processing makes it integral to various cellular processes that require accurate RNA management.

Biological function summary

ERI3 decapsulates mRNA influencing mRNA stability and turnover. This function positions ERI3 as essential in mRNA decay mechanisms. ERI3 doesn't work in isolation; it forms part of a multi-protein complex involved in mRNA decay and RNA processing activities. Studies suggest that it interacts directly with other key proteins in these complexes contributing to its biological significance.

Pathways

ERI3 plays a role in RNA degradation and nonsense-mediated mRNA decay pathways. It contributes to these pathways by interacting with proteins such as DCP2 and XRN1 which are important for mRNA turnover. This involvement ensures that cells maintain their mRNA levels and quality affecting overall protein synthesis necessary for cellular function.

Associated diseases and disorders

ERI3 shows a connection to liver cancer where its dysregulation impacts RNA decay processes linked to tumorigenesis. Another disorder associated with ERI3 is hereditary hemochromatosis although the connection is still under exploration. Within liver cancer the protein's relationship with DCP2 may influence disease progression highlighting ERI3's potential as a therapeutic target or biomarker.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

1 product image

  • Sanger Sequencing - Human ERI3 knockout HeLa cell line (ab265999), expandable thumbnail

    Sanger Sequencing - Human ERI3 knockout HeLa cell line (ab265999)

    Homozygous: 279 bp deletion in exon 1.

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com